Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CASI CASI Pharmaceuticals	$2.38 +22.7%	$1.50	$1.09 ▼ $7.67	$29.27M	0.63	3.43 million shs	6.05 million shs
CVKD Cadrenal Therapeutics	$12.68 -1.9%	$11.98	$5.70 ▼ $22.90	$25.96M	0.93	30,982 shs	29,643 shs
FRTX Fresh Tracks Therapeutics	$0.94 -0.5%	$0.94	$0.03 ▼ $1.03	$5.59M	0.54	2,709 shs	2,402 shs
RVPH Reviva Pharmaceuticals	$0.54 +15.8%	$0.51	$0.30 ▼ $4.28	$25.92M	-0.05	2.21 million shs	13.68 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CASI CASI Pharmaceuticals	0.00%	+46.01%	+84.50%	+22.62%	-62.16%
CVKD Cadrenal Therapeutics	0.00%	+13.72%	+6.82%	-18.19%	+1,267,999,900.00%
FRTX Fresh Tracks Therapeutics	0.00%	0.00%	0.00%	0.00%	+6.25%
RVPH Reviva Pharmaceuticals	0.00%	+32.65%	+33.27%	-34.15%	-24.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CASI CASI Pharmaceuticals	4.0861 of 5 stars	3.5	3.0	0.0	4.3	2.7	1.7	0.0
CVKD Cadrenal Therapeutics	2.9314 of 5 stars	3.5	3.0	0.0	0.0	3.1	1.7	0.6
FRTX Fresh Tracks Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	2.9119 of 5 stars	3.6	1.0	0.0	0.0	2.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	68.07% Upside
CVKD Cadrenal Therapeutics	3.00	Buy	$32.00	152.37% Upside
FRTX Fresh Tracks Therapeutics	0.00	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	3.25	Buy	$8.00	1,381.48% Upside

Current Analyst Ratings Breakdown

Latest FRTX, CVKD, CASI, and RVPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	RVPH Reviva Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/15/2025	RVPH Reviva Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
6/27/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/3/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/20/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $3.00
5/19/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CASI CASI Pharmaceuticals	$31.37M	0.93	N/A	N/A	$0.12 per share	19.83
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$2.10 per share	N/A
FRTX Fresh Tracks Therapeutics	$10.06M	0.56	N/A	N/A	$1.66 per share	0.56
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CASI CASI Pharmaceuticals	-$39.26M	-$2.55	N/A	∞	N/A	-129.05%	-972.55%	-77.33%	N/A
CVKD Cadrenal Therapeutics	-$10.65M	-$8.88	N/A	N/A	N/A	N/A	-265.37%	-196.38%	N/A
FRTX Fresh Tracks Therapeutics	-$5.69M	-$1.41	N/A	∞	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	-$29.92M	-$0.65	N/A	N/A	N/A	N/A	N/A	-269.23%	N/A

Latest FRTX, CVKD, CASI, and RVPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	RVPH Reviva Pharmaceuticals	-$0.15	-$0.12	+$0.03	-$0.12	N/A	N/A
8/11/2025	Q2 2025	CVKD Cadrenal Therapeutics	-$1.60	-$1.87	-$0.27	-$1.87	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
FRTX Fresh Tracks Therapeutics	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CASI CASI Pharmaceuticals	N/A	0.81	0.68
CVKD Cadrenal Therapeutics	N/A	3.55	4.32
FRTX Fresh Tracks Therapeutics	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	0.54	0.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CASI CASI Pharmaceuticals	22.23%
CVKD Cadrenal Therapeutics	7.92%
FRTX Fresh Tracks Therapeutics	25.04%
RVPH Reviva Pharmaceuticals	63.18%

Insider Ownership

Company	Insider Ownership
CASI CASI Pharmaceuticals	21.24%
CVKD Cadrenal Therapeutics	26.09%
FRTX Fresh Tracks Therapeutics	0.23%
RVPH Reviva Pharmaceuticals	27.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
CVKD Cadrenal Therapeutics	4	2.05 million	1.51 million	Not Optionable
FRTX Fresh Tracks Therapeutics	20	5.97 million	5.96 million	Not Optionable
RVPH Reviva Pharmaceuticals	5	48.00 million	34.96 million	Optionable

FRTX, CVKD, CASI, and RVPH Headlines

Recent News About These Companies

Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Rating Upgraded by Wall Street Zen

August 16 at 2:38 AM | americanbankingnews.com

Reviva Narrows Loss 23% in Fiscal Q2

August 14 at 12:07 AM | aol.comA

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 14 at 4:25 PM | globenewswire.com

Reviva Pharmaceuticals (RVPH) Expected to Announce Quarterly Earnings on Wednesday

August 12, 2025 | americanbankingnews.com

Reviva Pharmaceuticals Holdings, Inc. (RVPHW) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.com

June 29, 2025 | investing.com

Reviva Dives on Stock Offering

June 26, 2025 | baystreet.ca

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

June 26, 2025 | globenewswire.com

Reviva Pharmaceuticals stock falls after announcing public offering

June 25, 2025 | za.investing.com

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

June 25, 2025 | globenewswire.com

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

June 5, 2025 | finance.yahoo.com

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 5, 2025 | globenewswire.com

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

June 2, 2025 | globenewswire.com

Reviva to Participate in Upcoming Investor Conferences in May 2025

May 20, 2025 | santelog.comS

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025 | globenewswire.com

Reviva to Participate in the A.G.P. Healthcare Company Showcase

May 13, 2025 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)

May 4, 2025 | theglobeandmail.com

Reviva to Participate in the Citizens Life Sciences Conference

April 29, 2025 | finance.yahoo.com

RVPH: M&A Deals Highlight Brilaroxazine Value

April 7, 2025 | finance.yahoo.com

Roth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)

April 5, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

FRTX, CVKD, CASI, and RVPH Company Descriptions

CASI Pharmaceuticals NASDAQ:CASI

$2.38 +0.44 (+22.68%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.00 -0.38 (-15.76%)

As of 08/15/2025 07:59 PM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Cadrenal Therapeutics NASDAQ:CVKD

$12.68 -0.24 (-1.86%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$12.48 -0.20 (-1.58%)

As of 08/15/2025 06:19 PM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Fresh Tracks Therapeutics NASDAQ:FRTX

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.54 +0.07 (+15.83%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.55 +0.01 (+0.93%)

As of 08/15/2025 07:59 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time